Indapamide retard as the medication of choice in elderly patients with arterial hypertension
https://doi.org/10.15829/1560-4071-2013-5-56-60
Abstract
The modern society faces a steady increase in the numbers of elderly people, which is associated with a range of social and medical problems. Age-related aspects of body anatomy and physiology, multiple comorbidity, and cognitive decline restrict the choice of medications in elderly patients. The paper discusses the need for the agreement between the choice of antihypertensive agents in elderly patients and the importance of organoprotection. From the evidence-based medicine standpoint, indapamide retard is considered as the medication which meets all the requirements for arterial hypertension treatment in elderly patients.
About the Authors
I. I. Chukaeva
N. I. Pirogov Russian National Medical Research University, Moscow, Russia
Russian Federation
Russian Federation
Ya. G. Spiryakina
N. I. Pirogov Russian National Medical Research University, Moscow, Russia
Russian Federation
Russian Federation
References
1. Veselkova I. N., Zemljanova E. V. Health problems and medical and social services for the elderly. Psychology of adulthood and aging. 2000; 1:76–88. (Веселкова И. Н., Землянова Е. В. Проблемы здоровья и медико-социального обслуживания пожилых людей. Психология зрелости и старения. 2000; 1:76–88).
2. Sundquist J., Winkleby M. A., Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American and white women and men: an analysis of NHANES III, 1988–1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001; 49 (2):109–16.
3. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360:1903–13.
4. Chazova I. E., Ratova L. G., Bojcov S. A. et al. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Systemic hypertension, 2010; 3:5–26. (Чазова И. Е., Ратова Л. Г., Бойцов С. А. и др. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3:5–26.
5. Appel L. J., Espeland M., Whelton P. K., et al. Trial of Nonpharmacologic Intervention in the Elderly (TONE). Design and rationale of a blood pressure control trial. Ann Epidemiol. 1995 Mar; 5 (2):119–29.
6. James J DiNicolantonio. Hydrochlorothiazide: is it a wise choice? Expert Opin. Pharmacother. 2012 Apr; 13 (6):807–14.
7. Baguet J. P., Legallicier B., Auquier P. et al. Updated Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure. Clin Drug Invest 2007; 27 (11):734–52.
8. London G., Schmieder R., Calvo C., et al. Indapamide SR versus candesartan and amlodipine in hypertension: the X–CELLENT Study. Am J Hypertens. 2006 Jan; 19 (1):113–21.
9. Bejot Y, et al. Cerebrovasc. Dis. 2010; 29:111–121.
10. Liu L., Wang Z., Gong L., et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens. Res. 2009; 32, 11:1032–40.
11. Nigel S., Beckett M. B., Ch B., et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887–98.
12. Rothwell P. M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938–48
13. Gosse Ph., Sheridan D., Zannad F., et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE Study. J. Hypertens. 2000; 18:1465–75.
14. Henry R. M., Kostense P. J., Bos G., et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn study. Kidney int. 2002; 62:1402–7.
15. Marre M., Garcia-Puig J., Kokot F., et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J. Hypertens. 2004; 22:1613–22.
16. ADVANCE Management Committee Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease: preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44:1118–20.
17. Marre M., Garcia-Puig J., Kokot F., et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Amer. J. Hypertens. 2007; 20:90–7.
18. Hiddo J., Heerspink L., Ninomiya T., et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur.Heart J. 2010; 31:2888–96.
19. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety. 2001; 24:1155–65.
20. Leonetti G., Emeriau J-P., Knauf H., et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Current Medical Research and Opinion. 2005; 21:37–46.
Review
For citations:
Chukaeva I.I., Spiryakina Ya.G. Indapamide retard as the medication of choice in elderly patients with arterial hypertension. Russian Journal of Cardiology. 2013;(5):56-60. (In Russ.) https://doi.org/10.15829/1560-4071-2013-5-56-60
Views:
1940
Email this article 